Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Stryker Corporation presented impressive financial results during their recent earnings call, driven by a robust demand for both procedures and capital, strong pipeline production, and the easing of macro constraints.</li><li>The company exceeded $20 billion in sales, marking another high-growth year, and reported over 11% sales growth in Q4 and for the full year.</li><li>Margin recovery continued as well, with a 13% compared to the full year of 2022, due to strong sales.</li></ul>

Stryker Corporation presented impressive financial results during their recent earnings call, driven by a robust demand for both procedures and capital, strong pipeline production, and the easing of macro constraints.The company exceeded $20 billion in sales, marking another high-growth year, and reported over 11% sales growth in Q4 and for the full year.Margin recovery continued as well, with a 13% compared to the full year of 2022, due to strong sales.

Stryker Corporation: Growing Adoption of Robotic Systems & Improving Ortho Market Outlook Are Green Signals! - Major Drivers

High Quality Stock Setups, Weekly Stock Bull Finder

Weekly Stock Bull Finder

High Quality Stock Setups

Finding high potential stock setups on quality companies

Thematic (Sector/Industry)

<ul><li>As we begin 2024, the past few week have been consumed with media chatter over the launch of new bitcoin ETF’s with predictions this would unleash a new bitcoin bull market, meanwhile price action in different market sectors have been off to surprisingly strong starts.</li><li>Regardless of your favorite market prognosticators’ forecast for 2024 (up, down, or sideways), catching emerging waves in the start of each year, especially paying attention to volume and price, can lead to significant outperformance.</li><li>For example, if you recall back to January 2023’s earnings call season, it featured an eye opening proclamation from Microsoft CEO Satya Nadella that “<em>We [Microsoft] fundamentally believe the next platform wave will be AI</em>” which came exactly one day before Microsoft announced its rumored $10B investment in OpenAI.</li></ul>

As we begin 2024, the past few week have been consumed with media chatter over the launch of new bitcoin ETF’s with predictions this would unleash a new bitcoin bull market, meanwhile price action in different market sectors have been off to surprisingly strong starts.Regardless of your favorite market prognosticators’ forecast for 2024 (up, down, or sideways), catching emerging waves in the start of each year, especially paying attention to volume and price, can lead to significant outperformance.For example, if you recall back to January 2023’s earnings call season, it featured an eye opening proclamation from Microsoft CEO Satya Nadella that “We [Microsoft] fundamentally believe the next platform wave will be AI” which came exactly one day before Microsoft announced its rumored $10B investment in OpenAI.

<ul><li>Stryker Corporation delivered a solid result and managed an all-around beat in the last quarter, experiencing robust organic sales growth at 9.2%.</li><li>Endoscopy also achieved a US organic sales growth of 10.6%, driven by communications and sustainability businesses, while Neurovascular and Neuro Cranial showcased solid performances.</li><li>Considering strong performance, a robust backlog for capital equipment, and positive procedure trends, Stryker's team expects full-year 2023 organic sales growth from 10% to 10.5%.</li></ul>

Stryker Corporation delivered a solid result and managed an all-around beat in the last quarter, experiencing robust organic sales growth at 9.2%.Endoscopy also achieved a US organic sales growth of 10.6%, driven by communications and sustainability businesses, while Neurovascular and Neuro Cranial showcased solid performances.Considering strong performance, a robust backlog for capital equipment, and positive procedure trends, Stryker's team expects full-year 2023 organic sales growth from 10% to 10.5%.

Stryker Corporation: How Strategic Acquisitions Propel Market Success! - Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>In November, <a href="https://www.smartkarma.com/entities/orthofix-medical-inc" target="_blank" data-smartkarma-citation="entities:1264:1" rel="noopener">Orthofix International Nv (OFIX US)</a> named Massimo Calafiore as incoming President and CEO. Mr. Calafiore has extensive knowledge in orthopedics and spine, and M&amp;A integration expertise.</li>
<li>Orthofix has performed well and operated smoothly following management transition. In 3Q23, revenue increased 61% YoY on a reported basis and 1% YoY on a pro forma basis to $184M.</li>
<li>The company expects to deliver much higher adjusted profits next year and to exit 2024 cash-flow positive from an estimated $100 million outflow for 2023.</li>
</ul>


In November, Orthofix International Nv (OFIX US) named Massimo Calafiore as incoming President and CEO. Mr. Calafiore has extensive knowledge in orthopedics and spine, and M&amp;A integration expertise.
Orthofix has performed well and operated smoothly following management transition. In 3Q23, revenue increased 61% YoY on a reported basis and 1% YoY on a pro forma basis to $184M.
The company expects to deliver much higher adjusted profits next year and to exit 2024 cash-flow positive from an estimated $100 million outflow for 2023.


Orthofix International (OFIX US): Limited Downside Likely; Looking Ahead to 2024 with New Management

<ul><li>Stryker Corporation delivered a strong result and managed an all-around beat in the last quarter, marked by robust organic sales growth of 11.9%.</li><li>US and international organic sales demonstrated strong momentum despite a slight unfavorable impact from foreign currency exchange.</li><li>Lastly, the company expects organic sales growth for the entire year and adjusted EPS, highlighting its strong performance and positive outlook.</li></ul>

Stryker Corporation delivered a strong result and managed an all-around beat in the last quarter, marked by robust organic sales growth of 11.9%.US and international organic sales demonstrated strong momentum despite a slight unfavorable impact from foreign currency exchange.Lastly, the company expects organic sales growth for the entire year and adjusted EPS, highlighting its strong performance and positive outlook.

Stryker Corporation: A Health Giant Flexing its Muscles in MedSurg and Neurotech! - Major Drivers

United States

Stryker Corporation develops, manufactures, and markets specialty surgical and medical products.  The Company's products include implants, biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Stryker Corp (SYK US)

Stryker Corporation: Growing Adoption of Robotic Systems & Improving Ortho Market Outlook Are Green Signals! - Major Drivers

Stryker Corporation presented impressive financial results during their recent earnings call, driven by a robust demand for both procedures and...

Baptista Research

Weekly Stock Bullfinder - Week of 1/15

As we begin 2024, the past few week have been consumed with media chatter over the launch of new bitcoin ETF’s with predictions this would unleash...

Weekly Stock Bull Finder

Stryker Corporation: How Strategic Acquisitions Propel Market Success! - Major Drivers

Stryker Corporation delivered a solid result and managed an all-around beat in the last quarter, experiencing robust organic sales growth at...

Baptista Research

Orthofix International (OFIX US): Limited Downside Likely; Looking Ahead to 2024 with New Management

Orthofix has named Massimo Calafiore as its new CEO, who will bring expertise in spine and orthopedics and M&A integration. The company expects...

Tina Banerjee

Stryker Corporation: A Health Giant Flexing its Muscles in MedSurg and Neurotech! - Major Drivers

Stryker Corporation delivered a strong result and managed an all-around beat in the last quarter, marked by robust organic sales growth of...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Stryker Corporation: Growing Adoption of Robotic Systems & Improving Ortho Market Outlook Are Green Signals! - Major Drivers

Stryker Corporation presented impressive financial results during their recent earnings call, driven by a robust demand for both procedures and...

Baptista Research

Weekly Stock Bullfinder - Week of 1/15

As we begin 2024, the past few week have been consumed with media chatter over the launch of new bitcoin ETF’s with predictions this would unleash...

Weekly Stock Bull Finder

Stryker Corporation: How Strategic Acquisitions Propel Market Success! - Major Drivers

Stryker Corporation delivered a solid result and managed an all-around beat in the last quarter, experiencing robust organic sales growth at...

Baptista Research

Orthofix International (OFIX US): Limited Downside Likely; Looking Ahead to 2024 with New Management

​Orthofix has named Massimo Calafiore as its new CEO, who will bring expertise in spine and orthopedics and M&A integration. The company expects...

Tina Banerjee

Stryker Corporation: A Health Giant Flexing its Muscles in MedSurg and Neurotech! - Major Drivers

Stryker Corporation delivered a strong result and managed an all-around beat in the last quarter, marked by robust organic sales growth of...

Baptista Research

Orthofix has named Massimo Calafiore as its new CEO, who will bring expertise in spine and orthopedics and M&A integration. The company expects...